The University of Southampton
University of Southampton Institutional Repository

TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status

TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status
TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status
Background: breast neoplasia displays complex patterns of whole-of-life disease progression, which are difficult to study using legacy data systems. Our timeline- and episode-structured breast cancer data set of 20,000 records allows direct visualisation of the entire documentary record of every patient. The embedded data mining module permits research into a wide range of patient cohorts by pathology, treatment and outcome.

Methods: we selected the cohort of patients aged between 15 and 75 with HER-2 –ve and HER-2 +ve breast cancer who were treated with neoadjuvant chemotherapy (NAC), with or without anti-HER2 therapy between 2002 and 2019. We also studied the patterns and time intervals (in months) of disease progression and response to treatment from primary diagnosis, through loco-regional recurrence and distant metastasis to final outcome.

Results: of 301 women with confirmed early stage breast cancer were treated with NAC over that time, 186 had HER2- and 115 had HER2+ tumours. The patterns and intervals of disease progression, as displayed on the Master Lifetrack, were mapped and measured for every patient. The proportions of patients with Her2+ve tumours receiving trastuzumab and analogues, and the tumour responses to treatment, were audited. The underlying data set was validated by review of the original records.

Conclusions: the whole-of-life timeline structured cancer data system introduces a new direction for clinical data visualisation, record management and user utility in surgical practice. This study validates the model as a tool for the better understanding of treatment effects and longitudinal behaviours in any selected range of cancer phenotypes.
0007-1323
Rahman, Fatima
a50a073c-50b5-4a43-bd57-0e178a2326ab
Copson, Ellen
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Hales, Alan
66a20906-7b0e-4d23-b65a-08932f23900b
Rew, David
36dcc3ad-2379-4b61-a468-5c623d796887
Rahman, Fatima
a50a073c-50b5-4a43-bd57-0e178a2326ab
Copson, Ellen
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Hales, Alan
66a20906-7b0e-4d23-b65a-08932f23900b
Rew, David
36dcc3ad-2379-4b61-a468-5c623d796887

Rahman, Fatima, Copson, Ellen, Hales, Alan and Rew, David (2021) TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status. British Journal of Surgery, 108 (Supplement_7). (doi:10.1093/bjs/znab362.069).

Record type: Meeting abstract

Abstract

Background: breast neoplasia displays complex patterns of whole-of-life disease progression, which are difficult to study using legacy data systems. Our timeline- and episode-structured breast cancer data set of 20,000 records allows direct visualisation of the entire documentary record of every patient. The embedded data mining module permits research into a wide range of patient cohorts by pathology, treatment and outcome.

Methods: we selected the cohort of patients aged between 15 and 75 with HER-2 –ve and HER-2 +ve breast cancer who were treated with neoadjuvant chemotherapy (NAC), with or without anti-HER2 therapy between 2002 and 2019. We also studied the patterns and time intervals (in months) of disease progression and response to treatment from primary diagnosis, through loco-regional recurrence and distant metastasis to final outcome.

Results: of 301 women with confirmed early stage breast cancer were treated with NAC over that time, 186 had HER2- and 115 had HER2+ tumours. The patterns and intervals of disease progression, as displayed on the Master Lifetrack, were mapped and measured for every patient. The proportions of patients with Her2+ve tumours receiving trastuzumab and analogues, and the tumour responses to treatment, were audited. The underlying data set was validated by review of the original records.

Conclusions: the whole-of-life timeline structured cancer data system introduces a new direction for clinical data visualisation, record management and user utility in surgical practice. This study validates the model as a tool for the better understanding of treatment effects and longitudinal behaviours in any selected range of cancer phenotypes.

This record has no associated files available for download.

More information

e-pub ahead of print date: 28 October 2021

Identifiers

Local EPrints ID: 455957
URI: http://eprints.soton.ac.uk/id/eprint/455957
ISSN: 0007-1323
PURE UUID: c01516d8-7695-4b1c-921b-681d0c37d6be
ORCID for David Rew: ORCID iD orcid.org/0000-0002-4518-2667

Catalogue record

Date deposited: 11 Apr 2022 16:37
Last modified: 17 Mar 2024 03:56

Export record

Altmetrics

Contributors

Author: Fatima Rahman
Author: Ellen Copson
Author: Alan Hales
Author: David Rew ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×